mms ben dudley

Ben is a seasoned executive with experience gained over a 27-year career in the industry, in both the biopharma and clinical development services sectors. Ben’s deep, broad expertise spans drug development, sales and customer relationship management, operational leadership, and process optimization. He has led truly global teams and diverse delivery portfolios.

Before joining MMS, Ben served as EVP, Head of Global Project Leadership at Parexel, where he was responsible for delivering the full-service clinical project portfolio globally, across biotech and large-pharma segments. Prior roles at Parexel included key sales leadership and strategic partnership positions with large pharma customers. His impressive career also includes leadership roles at Covance and AstraZeneca, where he consistently demonstrated his ability to lead and innovate across various operational, functional, and commercial domains.

The company holds a significant place in the global CRO landscape, and I have witnessed the strength of their expertise over the years. I relish the opportunity to be part of the leadership of an organization with unique capabilities and culture as we continue the next stage of growth and delivery for our customers.
Ben Dudley
Chief Commercial Officer

Ben’s extensive industry experience, particularly in drug development and customer relationship management, equips him with the agility and effectiveness needed to help MMS continue its forward momentum. As CCO, Ben is accountable for all Commercial, Sales and Marketing functions, and strategic growth planning to continually enhance the value of MMS service offerings to our customers and ultimately patients.

Suggested For You

news

May 28th, 2025

MMS Named Finalist for Fierce CRO Award in Excellence in Client Service and Partnership, CEO shortlisted for the CRO Champion Award 

perspectives

May 28th, 2025

A Season of Change: Why the REMS Industry Consortium Matters More Than Ever

perspectives

May 20th, 2025

Navigating FDA OMOR Meetings: A Comprehensive Guide to Type X, Y, and Z Meetings for OTC Drug Sponsors

perspectives

May 6th, 2025

Why Clinical Trial Simulation Is Reshaping Drug Development: A Q&A with Dr. Aiden Flynn

perspectives

April 24th, 2025

How to Derisk Clinical Development with Unified Trial Design and Regulatory Strategy

perspectives

April 8th, 2025

Updated UK Clinical Trial Regulation: The Key Changes and Impact on Development Safety Update Report (DSUR) Requirements

news

April 3rd, 2025

Datacise by MMS Wins 2025 Data Breakthrough Award for Best Data Science Solution

perspectives

March 27th, 2025

Enhancing Drug Safety Through Digital Solutions: Innovative Technologies in FDA REMS Programs

news

March 19th, 2025

MMS REMS-focused Technology bolsters Full-Service REMS Solutions

webinar

April 30th, 2025

Advancing Clinical Development with Innovative Trial Design and Regulatory Strategies

perspectives

March 6th, 2025

Overview of FDA Guidance for Industry on Assessment of Ovarian Toxicity in Premenopausal Adults During Development for Oncologic Products

webinar

March 25th, 2025

Overcoming NDA/BLA Submission Challenges: Practical Strategies for Success